Oral ENT-01 Targets Enteric Neurons to Treat Constipation in Parkinson Disease : A Randomized Controlled Trial

doi:10.7326/M22-1438

Randomized Controlled Trial

. 2022 Dec;175(12):1666-1674.

doi: 10.7326/M22-1438. Epub 2022 Nov 8.

Oral ENT-01 Targets Enteric Neurons to Treat Constipation in Parkinson Disease : A Randomized Controlled Trial

Michael Camilleri¹, Thyagarajan Subramanian², Fernando Pagan³, Stuart Isaacson⁴, Ramon Gil⁵, Robert A Hauser⁶, Mary Feldman⁷, Mark Goldstein⁸, Rajeev Kumar⁹, Daniel Truong¹⁰, Nisha Chhabria¹¹, Benjamin L Walter¹², Jonathan Eskenazi¹³, Robert Riesenberg¹⁴, Daniel Burdick¹⁵, Winona Tse¹⁶, Eric Molho¹⁷, Bradley Robottom¹⁸, Perminder Bhatia¹⁹, Srinath Kadimi²⁰, Kevin Klos²¹, David Shprecher²², Otto Marquez-Mendoza²³, Gonzalo Hidalgo²⁴, Stephen Grill²⁵, George Li²⁶, Howard Mandell²⁷, Mary Hughes²⁸, Sharisse Stephenson²⁹, Joel Vandersluis³⁰, Michael Pfeffer³¹, Andrew Duker³², Vikram Shivkumar³³, William Kinney³⁴, James MacDougall³⁵, Michael Zasloff³⁶, Denise Barbut³⁷

Affiliations

¹ Mayo Clinic, Rochester, Minnesota (M.C.).
² Penn State Hershey Medical Center, Hershey, Pennsylvania (T.S.).
³ Department of Neurology, Georgetown University Hospital, Washington, DC (F.P.).
⁴ Parkinson's Disease and Movement Disorder Center of Boca Raton, Boca Raton, Florida (S.I.).
⁵ Parkinson's Disease Treatment Center of SW Florida, Port Charlotte, Florida (R.G.).
⁶ USF Parkinson's Disease and Movement Disorder Center, Tampa, Florida (R.A.H.).
⁷ Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire (M.F.).
⁸ JEM Headlands Research Institute, Atlantis, Florida (M.G.).
⁹ Rocky Mountain Movement Disorder Center, Englewood, Colorado (R.K.).
¹⁰ The Parkinson's and Movement Disorder Institute, Fountain Valley, California (D.T.).
¹¹ Palm Beach Neurology and Premiere Research Institute, West Palm Beach, Florida (N.C.).
¹² Parkinson's and Movement Disorders Center, Cleveland Clinic, Cleveland, Ohio (B.L.W.).
¹³ SC3 Research Group, Pasadena, California (J.E.).
¹⁴ Atlanta Center for Medical Research, Atlanta, Georgia (R.R.).
¹⁵ Booth Gardner Parkinson's Care Center, EvergreenHealth, Kirkland, Washington (D.B.).
¹⁶ Parkinson's and Movement Disorders Center, Icahn School of Medicine at Mount Sinai, New York, New York (W.T.).
¹⁷ Parkinson's Disease and Movement Center, Albany Medical College, Albany, New York (E.M.).
¹⁸ Raleigh Neurology Associates, Raleigh, North Carolina (B.R.).
¹⁹ Neuro Pain Medical Center, Fresno, California (P.B.).
²⁰ Associated Neurologists of Southern Connecticut, Fairfield, Connecticut (S.K.).
²¹ The Movement Disorder Clinic of Oklahoma, Tulsa, Oklahoma (K.K.).
²² Banner Sun Health Research Institute, Sun City, Arizona (D.S.).
²³ Elias Research - Pharmax Research of South Florida, Inc., Miami, Florida (O.M.).
²⁴ The Neuromedical Clinic of Central Louisiana, Alexandria, Louisiana (G.H.).
²⁵ Parkinson's and Movement Disorders Center of Maryland, Elkridge, Maryland (S.G.).
²⁶ MEDSOL Clinical Research, Port Charlotte, Florida (G.L.).
²⁷ Metrolina Neurological Associates, Indian Land, South Carolina (H.M.).
²⁸ Premier Neurology, Greer, South Carolina (M.H.).
²⁹ BTC Network, Neurologic Associates of North Texas, Dallas, Texas (S.S.).
³⁰ Elias Research, Neurology Diagnostics, Inc., Dayton, Ohio (J.V.).
³¹ Allied Biomedical Neurologic Research Institute, Miami, Florida (M.P.).
³² University of Cincinnati, Cincinnati, Ohio (A.D.).
³³ University Physicians and Surgeons, Inc., Marshall Health, Huntington, West Virginia (V.S.).
³⁴ Enterin, Inc., Philadelphia, Pennsylvania (W.K.).
³⁵ MacDougall Statistical Institute, Haverhill, Massachusetts (J.M.).
³⁶ Medstar-Georgetown Transplant Institute, Washington, DC, and Enterin Research Institute and Enterin, Inc., Philadelphia, Pennsylvania (M.Z.).
³⁷ Enterin Research Institute and Enterin, Inc., Philadelphia, Pennsylvania (D.B.).

PMID: 36343348
DOI: 10.7326/M22-1438

Randomized Controlled Trial

Oral ENT-01 Targets Enteric Neurons to Treat Constipation in Parkinson Disease : A Randomized Controlled Trial

Michael Camilleri et al. Ann Intern Med. 2022 Dec.

. 2022 Dec;175(12):1666-1674.

doi: 10.7326/M22-1438. Epub 2022 Nov 8.

Authors

Affiliations

¹ Mayo Clinic, Rochester, Minnesota (M.C.).
² Penn State Hershey Medical Center, Hershey, Pennsylvania (T.S.).
³ Department of Neurology, Georgetown University Hospital, Washington, DC (F.P.).
⁴ Parkinson's Disease and Movement Disorder Center of Boca Raton, Boca Raton, Florida (S.I.).
⁵ Parkinson's Disease Treatment Center of SW Florida, Port Charlotte, Florida (R.G.).
⁶ USF Parkinson's Disease and Movement Disorder Center, Tampa, Florida (R.A.H.).
⁷ Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire (M.F.).
⁸ JEM Headlands Research Institute, Atlantis, Florida (M.G.).
⁹ Rocky Mountain Movement Disorder Center, Englewood, Colorado (R.K.).
¹⁰ The Parkinson's and Movement Disorder Institute, Fountain Valley, California (D.T.).
¹¹ Palm Beach Neurology and Premiere Research Institute, West Palm Beach, Florida (N.C.).
¹² Parkinson's and Movement Disorders Center, Cleveland Clinic, Cleveland, Ohio (B.L.W.).
¹³ SC3 Research Group, Pasadena, California (J.E.).
¹⁴ Atlanta Center for Medical Research, Atlanta, Georgia (R.R.).
¹⁵ Booth Gardner Parkinson's Care Center, EvergreenHealth, Kirkland, Washington (D.B.).
¹⁶ Parkinson's and Movement Disorders Center, Icahn School of Medicine at Mount Sinai, New York, New York (W.T.).
¹⁷ Parkinson's Disease and Movement Center, Albany Medical College, Albany, New York (E.M.).
¹⁸ Raleigh Neurology Associates, Raleigh, North Carolina (B.R.).
¹⁹ Neuro Pain Medical Center, Fresno, California (P.B.).
²⁰ Associated Neurologists of Southern Connecticut, Fairfield, Connecticut (S.K.).
²¹ The Movement Disorder Clinic of Oklahoma, Tulsa, Oklahoma (K.K.).
²² Banner Sun Health Research Institute, Sun City, Arizona (D.S.).
²³ Elias Research - Pharmax Research of South Florida, Inc., Miami, Florida (O.M.).
²⁴ The Neuromedical Clinic of Central Louisiana, Alexandria, Louisiana (G.H.).
²⁵ Parkinson's and Movement Disorders Center of Maryland, Elkridge, Maryland (S.G.).
²⁶ MEDSOL Clinical Research, Port Charlotte, Florida (G.L.).
²⁷ Metrolina Neurological Associates, Indian Land, South Carolina (H.M.).
²⁸ Premier Neurology, Greer, South Carolina (M.H.).
²⁹ BTC Network, Neurologic Associates of North Texas, Dallas, Texas (S.S.).
³⁰ Elias Research, Neurology Diagnostics, Inc., Dayton, Ohio (J.V.).
³¹ Allied Biomedical Neurologic Research Institute, Miami, Florida (M.P.).
³² University of Cincinnati, Cincinnati, Ohio (A.D.).
³³ University Physicians and Surgeons, Inc., Marshall Health, Huntington, West Virginia (V.S.).
³⁴ Enterin, Inc., Philadelphia, Pennsylvania (W.K.).
³⁵ MacDougall Statistical Institute, Haverhill, Massachusetts (J.M.).
³⁶ Medstar-Georgetown Transplant Institute, Washington, DC, and Enterin Research Institute and Enterin, Inc., Philadelphia, Pennsylvania (M.Z.).
³⁷ Enterin Research Institute and Enterin, Inc., Philadelphia, Pennsylvania (D.B.).

PMID: 36343348
DOI: 10.7326/M22-1438

Erratum in

Correction: Oral ENT-01 Targets Enteric Neurons to Treat Constipation in Parkinson Disease.
[No authors listed] [No authors listed] Ann Intern Med. 2023 Jan;176(1):144. doi: 10.7326/L22-0464. Epub 2022 Dec 20. Ann Intern Med. 2023. PMID: 36598175 No abstract available.

Abstract

Background: Parkinson disease (PD) is associated with α-synuclein (αS) aggregation within enteric neurons. ENT-01 inhibits the formation of αS aggregates and improved constipation in an open-label study in patients with PD.

Objective: To evaluate the safety and efficacy of oral ENT-01 for constipation and neurologic symptoms in patients with PD and constipation.

Design: Randomized, placebo-controlled phase 2b study. (ClinicalTrials.gov: NCT03781791).

Setting: Outpatient.

Patients: 150 patients with PD and constipation.

Intervention: ENT-01 or placebo daily for up to 25 days. After baseline assessment of constipation severity, daily dosing was escalated to the prokinetic dose, the maximum dose (250 mg), or the tolerability limit, followed by a washout period.

Measurements: The primary efficacy end point was the number of complete spontaneous bowel movements (CSBMs) per week. Neurologic end points included dementia (assessed using the Mini-Mental State Examination [MMSE]) and psychosis (assessed using the Scale for the Assessment of Positive Symptoms adapted for PD [SAPS-PD]).

Results: The weekly CSBM rate increased from 0.7 to 3.2 in the ENT-01 group versus 0.7 to 1.2 in the placebo group (P < 0.001). Improvement in secondary end points included SBMs (P = 0.002), stool consistency (P < 0.001), ease of passage (P = 0.006), and laxative use (P = 0.041). In patients with dementia, MMSE scores improved by 3.4 points 6 weeks after treatment in the ENT-01 group (n = 14) versus 2.0 points in the placebo group (n = 14). Among patients with psychosis, SAPS-PD scores improved from 6.5 to 1.7 six weeks after treatment in the ENT-01 group (n = 5) and from 6.3 to 4.4 in the placebo group (n = 6). ENT-01 was well tolerated, with no deaths or drug-related serious adverse events. Adverse events were predominantly gastrointestinal, including nausea (34.4% [ENT-01] vs. 5.3% [placebo]; P < 0.001) and diarrhea (19.4% [ENT-01] vs. 5.3% [placebo]; P = 0.016).

Limitation: Longer treatment periods need to be investigated in future studies.

Conclusion: ENT-01 was safe and significantly improved constipation.

Primary funding source: Enterin, Inc.

PubMed Disclaimer

Comment in

Targeting the Enteric Nervous System to Treat Constipation in Parkinson's Disease.
Keszthelyi D. Keszthelyi D. Gastroenterology. 2023 May;164(6):1017-1018. doi: 10.1053/j.gastro.2022.12.036. Epub 2023 Jan 3. Gastroenterology. 2023. PMID: 36608716 No abstract available.

Cited by

Small Molecules, α-Synuclein Pathology, and the Search for Effective Treatments in Parkinson's Disease.
Sechi GP, Sechi MM. Sechi GP, et al. Int J Mol Sci. 2024 Oct 18;25(20):11198. doi: 10.3390/ijms252011198. Int J Mol Sci. 2024. PMID: 39456980 Free PMC article. Review.
Aggregation of the amyloid-β peptide (Aβ40) within condensates generated through liquid-liquid phase separation.
Morris OM, Toprakcioglu Z, Röntgen A, Cali M, Knowles TPJ, Vendruscolo M. Morris OM, et al. Sci Rep. 2024 Sep 30;14(1):22633. doi: 10.1038/s41598-024-72265-7. Sci Rep. 2024. PMID: 39349560 Free PMC article.
Pharmacokinetics and Enterohepatic Circulation of 2-(Quinoline-8-carboxamido)benzoic Acid (2-QBA) in Mice.
Jeon JH, Jeon SY, Baek YJ, Park CE, Choi MK, Han YT, Song IS. Jeon JH, et al. Pharmaceutics. 2024 Jul 12;16(7):934. doi: 10.3390/pharmaceutics16070934. Pharmaceutics. 2024. PMID: 39065631 Free PMC article.
Relationship among Parkinson's disease, constipation, microbes, and microbiological therapy.
Yuan XY, Chen YS, Liu Z. Yuan XY, et al. World J Gastroenterol. 2024 Jan 21;30(3):225-237. doi: 10.3748/wjg.v30.i3.225. World J Gastroenterol. 2024. PMID: 38314132 Free PMC article. Review.
Management of Gastrointestinal Symptoms in Parkinson's Disease: A Comprehensive Review of Clinical Presentation, Workup, and Treatment.
Pasricha TS, Guerrero-Lopez IL, Kuo B. Pasricha TS, et al. J Clin Gastroenterol. 2024 Mar 1;58(3):211-220. doi: 10.1097/MCG.0000000000001961. J Clin Gastroenterol. 2024. PMID: 38260966 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Associated data

Actions
- Search in PubMed
- Search in ClinicalTrials.gov

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Oral ENT-01 Targets Enteric Neurons to Treat Constipation in Parkinson Disease : A Randomized Controlled Trial

Affiliations

Oral ENT-01 Targets Enteric Neurons to Treat Constipation in Parkinson Disease : A Randomized Controlled Trial

Authors

Affiliations

Erratum in

Abstract

Comment in

Similar articles

Cited by

Publication types

MeSH terms

Associated data

LinkOut - more resources

Full Text Sources

Medical

Research Materials

Miscellaneous

Erratum in

Abstract

Comment in

Similar articles

Cited by

Publication types

MeSH terms

Associated data

Related information

LinkOut - more resources

Full Text Sources

Medical

Research Materials

Miscellaneous